Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?

about

Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?

Item

http://www.wikidata.org/entity/Q36508284

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Minimal residual disease detec ...... point over molecular biology?

@ast

Minimal residual disease detec ...... point over molecular biology?

@en

type

Item

label

Minimal residual disease detec ...... point over molecular biology?

@ast

Minimal residual disease detec ...... point over molecular biology?

@en

prefLabel

Minimal residual disease detec ...... point over molecular biology?

@ast

Minimal residual disease detec ...... point over molecular biology?

@en

P1476

Minimal residual disease detec ...... point over molecular biology?

@en

P2093

Adriano Venditti

http://www.w3.org/2001/XMLSchema#string

Francesco Buccisano

http://www.w3.org/2001/XMLSchema#string

Luca Maurillo

http://www.w3.org/2001/XMLSchema#string

Maria Ilaria Del Principe

http://www.w3.org/2001/XMLSchema#string

Sergio Amadori

http://www.w3.org/2001/XMLSchema#string

P2860

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

The incidence and clinical significance of nucleophosmin mutations in childhood AML.

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

P304

43-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2224-4336.2012.10.01

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26835284

http://www.w3.org/2001/XMLSchema#string

P932

4728949

http://www.w3.org/2001/XMLSchema#string